- 1.
World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Lest 24.3.2020.
- 2.
Folkehelseinstituttet. Hjerte-og karregisteret: Rapport for 2012–2016. https://www.fhi.no/publ/2018/hjerte--og-karregisteret-rapport-for-20122016/ Lest 24.3.2020.
- 3.
Barquera S, Pedroza-Tobías A, Medina C et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res 2015; 46: 328–38. [PubMed][CrossRef]
- 4.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–88. [PubMed][CrossRef]
- 5.
VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004; 24: 12–22. [PubMed][CrossRef]
- 6.
Wight TN. A role for proteoglycans in vascular disease. Matrix Biol 2018; 71-72: 396–420. [PubMed][CrossRef]
- 7.
Zhang X, Sun D, Song JW et al. Endothelial cell dysfunction and glycocalyx - A vicious circle. Matrix Biol 2018; 71-72: 421–31. [PubMed][CrossRef]
- 8.
Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci Transl Med 2018; 10: eaao0475. [PubMed][CrossRef]
- 9.
Kolset SO. Proteoglykaner–finnes overalt i kroppen og har mange funksjoner. Tidsskr Nor Laegeforen 1989; 109: 2567–71. [PubMed]
- 10.
Gordts PLSM, Esko JD. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biol 2018; 71-72: 262–82. [PubMed][CrossRef]
- 11.
Hultgårdh-Nilsson A, Borén J, Chakravarti S. The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis. J Intern Med 2015; 278: 447–61. [PubMed][CrossRef]
- 12.
Gustafsen C, Olsen D, Vilstrup J et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 2017; 8: 503. [PubMed][CrossRef]
- 13.
Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–22. [PubMed][CrossRef]
- 14.
Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–99. [PubMed][CrossRef]
- 15.
Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551–61. [PubMed][CrossRef]
- 16.
Zeng X, Chen J, Miller YI et al. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J Lipid Res 2005; 46: 1849–59. [PubMed][CrossRef]
- 17.
Soto Y, Acosta E, Delgado L et al. Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans. Arterioscler Thromb Vasc Biol 2012; 32: 595–604. [PubMed][CrossRef]
()